These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. FDA perspective on specifications for biotechnology products--from IND to PLA. Murano G Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677 [TBL] [Abstract][Full Text] [Related]
7. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective. Zhuang Y; Chen D; Sharma A; Xu Z AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224 [TBL] [Abstract][Full Text] [Related]
8. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650 [TBL] [Abstract][Full Text] [Related]
9. Basic regulatory science behind drug substance and drug product specifications of monoclonal antibodies and other protein therapeutics. Limpikirati PK; Mongkoltipparat S; Denchaipradit T; Siwasophonpong N; Pornnopparat W; Ramanandana P; Pianpaktr P; Tongchusak S; Tian MT; Pisitkun T J Pharm Anal; 2024 Jun; 14(6):100916. PubMed ID: 39035218 [TBL] [Abstract][Full Text] [Related]
11. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations. Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512 [TBL] [Abstract][Full Text] [Related]
12. Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research. J Immunother; 1997 May; 20(3):214-43. PubMed ID: 9181460 [No Abstract] [Full Text] [Related]
14. CMC Regulatory Considerations for Antibody-Drug Conjugates. Bechtold-Peters K; Ruggiero A; Vriezen N; Ihle N; Klein A; Morgan C; Schweizer D; Liu D; Jacobson F; Buecheler J; Panek M; Duggan N; Malyala P; Dupraz P; Desai P; Niu S; Feng Y; Wang X J Pharm Sci; 2023 Dec; 112(12):2965-2980. PubMed ID: 37741455 [TBL] [Abstract][Full Text] [Related]
15. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies. Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375 [TBL] [Abstract][Full Text] [Related]
16. Methods to Make Homogenous Antibody Drug Conjugates. Kline T; Steiner AR; Penta K; Sato AK; Hallam TJ; Yin G Pharm Res; 2015 Nov; 32(11):3480-93. PubMed ID: 25511917 [TBL] [Abstract][Full Text] [Related]
17. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth report. World Health Organ Tech Rep Ser; 2016; (996):1-358, back cover. PubMed ID: 27514184 [TBL] [Abstract][Full Text] [Related]
18. Vapor Phase Hydrogen Peroxide Decontamination or Sanitization of an Isolator for Aseptic Filling of Monoclonal Antibody Drug Product-Hydrogen Peroxide Uptake and Impact on Protein Quality. Hubbard A; Roedl T; Hui A; Knueppel S; Eppler K; Lehnert S; Maa YF PDA J Pharm Sci Technol; 2018; 72(4):348-366. PubMed ID: 29545321 [TBL] [Abstract][Full Text] [Related]
19. Appropriate specifications at the IND stage. Geigert J PDA J Pharm Sci Technol; 1997; 51(2):78-80. PubMed ID: 9146038 [TBL] [Abstract][Full Text] [Related]
20. A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies. Demmon S; Bhargava S; Ciolek D; Halley J; Jaya N; Joubert MK; Koepf E; Smith P; Trexler-Schmidt M; Tsai P Biologicals; 2020 Sep; 67():9-20. PubMed ID: 32665104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]